hotspot -WSS

hotspot

author：fashion 2025-10-01 14:19:47 - browse：36

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Childhood cancer progress stalls for Black, Hispanic kids: Report

hotspot

WSS

A daunting task: navigating dual Medicare, Medicaid eligibility

STAT Readout Newsletter: Today's biggest biotech updates

Wegovy, Zepbound and weight loss drugs that preserve muscle

Morphosys mixed study results for blood cancer drug

NIH confirmation hearing shows politicization of research

STAT Summit: Biotech founders on deal

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Drug repurposing or repositioning? The language matters

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Walensky prepares to leave CDC — and Congress — behind

In key trial, Verve's treatment lowers cholesterol levels in patients

Supreme Court strikes down use of affirmative action

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Walensky prepares to leave CDC — and Congress — behind

In key trial, Verve's treatment lowers cholesterol levels in patients

Drug repurposing or repositioning? The language matters

UnitedHealth’s board chair also owns a personal investment firm

knowledge

David Sabatini, ex

First Opinion Podcast: Long Covid needs a new approach

PBM reforms clear House panel

First Opinion Podcast: Long Covid needs a new approach

Studies point to risks of excluding people with obesity from drug trials

Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

knowledge

hotspot

Wikipedia